💊 Bajaj Healthcare FY25 Results: Flatlining Growth, Flatlining Stock – Will This Pharma Underdog Ever Get a Break?
📌 At a glance: Bajaj Healthcare Ltd reported a flat FY25 revenue of ₹393 crore (vs ₹392 crore in FY24), and a 12% decline in PAT to ₹34.84 crore. Margins shrank. Cash flow dipped. The stock responded with a 7.4% drop to ₹558.15. But wait – there’s a twist: the company declared a ₹3.50/share dividend, and promoters keep hiking stake. So is this a sleeping compounder… or just sedated?
đź’Ľ About the Company
Bajaj Healthcare Ltd is a vertically integrated pharma and nutraceuticals company that manufactures:
APIs (Active Pharmaceutical Ingredients)
Intermediates
Finished formulations
Nutraceuticals
It exports to 50+ countries and plays in therapeutic segments like cardio, anti-infective, anti-malarial, anti-diabetic, and more. Oh, and they love acronyms almost as much as they love slow-moving balance sheets.
🧑⚕️ Key Managerial Personnel (KMP)
Anil Jain – Chairman & MD
Bimal Jain – Joint Managing Director
Rakesh Shah – CFO
Lalitkumar Sonawane – Company Secretary
Together, they’re fighting inflation, global supply pressures… and investor apathy.
